Cytokinetics Inc (CYTK)
Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
CYTK SEC Filing Email Alerts Service
| Company Name: |
Cytokinetics Inc |
| Website: |
www.cytokinetics.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding CYTK: |
48 |
| Total Market Value Held by ETFs: |
$1.29B |
| Total Market Capitalization: |
$7.11B |
| % of Market Cap. Held by ETFs: |
18.20% |
|
|
April 18, 2024 • 11:08 AM Eastern
Strong Buy (3.56 out of 4)
100th percentile
|
|
Free CYTK Email Alerts:
